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Abstract
The oxidative process of LDL particles generates molecules which are structurally similar to platelet-activating factor (PAF),
and some effects of oxidized LDL (oxLDL) have been shown to be dependent on PAF receptor (PAFR) activation. In a
previous study, we showed that PAFR is required for upregulation of CD36 and oxLDL uptake. In the present study we
analyzed the molecular mechanisms activated by oxLDL in human macrophages and the contribution of PAFR to this
response. Human adherent monocytes/macrophages were stimulated with oxLDL. Uptake of oxLDL and CD36 expression
were determined by flow cytometry; MAP kinases and Akt phosphorylation by Western blot; IL-8 and MCP-1 concentration
by ELISA and mRNA expression by real-time PCR. To investigate the participation of the PI3K/Akt pathway, Gai-coupled
protein or PAFR, macrophages were treated with LY294002, pertussis toxin or with the PAFR antagonists WEB2170 and
CV3988, respectively before addition of oxLDL. It was found that the addition of oxLDL to human monocytes/macrophages
activates the PI3K/Akt pathway which in turn activates the MAPK (p38 and JNK). Phosphorylation of Akt requires the
engagement of PAFR and a Gai-coupled protein. The upregulation of CD36 protein and the uptake of oxLDL as well as the
IL-8 production are dependent on PI3K/Akt pathway activation. The increased CD36 protein expression is dependent on
PAFR and Gai-coupled protein. Transfection studies using HEK 293t cells showed that oxLDL uptake occurs with either PAFR
or CD36, but IL-8 production requires the co-transfection of both PAFR and CD36. These findings show that PAFR has a
pivotal role in macrophages response to oxLDL and suggest that pharmacological intervention at the level of PAFR
activation might be beneficial in atherosclerosis.
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Introduction
Accumulation of modified low-density lipoprotein (LDL), such
as oxidized LDL (oxLDL), in the arterial wall, and the recruitment
of monocytes to the subendothelial space are known to be the
main early events in the development of atherosclerosis [1].
Macrophages express receptors that bind and internalize oxidized
forms of LDL. It is known that CD36 receptor expression is not
regulated by intracellular levels of cholesterol, and is increased in
atherosclerotic lesions because of auto-regulation by components
of the oxLDL particles [2]. This uncontrolled uptake leads to
differentiation of the macrophage into foam cells that play a
critical role in development and progression of the atherosclerotic
plaque [3].
A number of laboratory studies have provided compelling
evidence that CD36 is one of the main scavenger receptors
involved in the uptake of oxLDL by monocytes/macrophages. Its
deficiency greatly reduced the uptake of oxLDL and atheroscle-
rotic lesions in mice models [4,5]. Moreover, monocytes from
individuals lacking CD36, or experiments using functional
blockage with antibodies, decreased oxLDL uptake by about
50% [4].
The mechanism of oxLDL-induced foam cell formation during
the atherosclerotic process has been under intense investigation,
and appears to be dependent on several membrane and nuclear
receptors that might act, either independently or synergistically, to
mediate the cell response [1,6]. The uptake of oxLDL leads to
activation of a MAPK pathway that exerts a crucial role in foam
cell formation and is essential for IL-8 production, which mediates
the cell recruitment to the plaque site, accelerating the atherogenic
process and arterial thickness [7]. Moreover, MAPK activation
has anti-apoptotic effects, contributing to macrophage prolifera-
tion and foam cell survival in the atherosclerotic plaque [8].
The oxidative process of LDL particles generates molecules
which are structurally similar to the lipid mediator platelet-
activating factor (PAF), and some effects of oxLDL have been
shown to be dependent on PAFR activation [9,10]. Although these
PAF-like compounds are less potent than PAF in binding to
PAFR, they are considerably more abundant [9]. Our previous
study revealed that oxLDL activates MAPK (ERK1/2 and JNK)
and increases the expression of CD36 in human cells by PAFR-
dependent mechanisms. Moreover we have shown that uptake of
oxLDL is also dependent on PAFR [11]. Since the main receptor
that mediates the oxLDL uptake by macrophages is CD36, which
has a very short intracytoplasmatic tail that hardly activates
intracellular signaling pathways, we hypothesized that the effect of
oxLDL might be caused by co-stimulation of CD36 and PAFR
[11]. In the present study, we confirmed this hypothesis by
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demonstrating the requirement of both receptors for macrophage
response to oxLDL and further investigated the molecular
mechanisms involved.
Results
oxLDL activates PI3K/Akt pathway in a PAFR and Gai-
coupled protein- dependent manner
Increasing evidence is emerging that the activation of PI3K and
its downstream effector Akt plays a role in macrophage activation
induced by oxLDL [12]. We therefore investigated whether PAFR
and a Gai-coupled protein are involved in this activation. Human
macrophages were pre-treated with WEB2170 for 30 min or with
PTX for 18 h and then stimulated with oxLDL. We found that
pre-treatment with a PAFR antagonist and PTX inhibited the Akt
phosphorylation (90% and 86% inhibition respectively) induced
by oxLDL (Fig. 1A and 1B).
In a previous study we showed that oxLDL induces the
activation of the MAPK pathway and that this effect is PAFR-
dependent [11]. We then tested whether PI3K activation is
required for MAPK phosphorylation. Human macrophages were
pre-treated with PI3K inhibitor LY294002 and stimulated with
oxLDL. It was found that oxLDL induced the phosphorylation of
ERK1/2, JNK and p38 (Fig. 2). Figures 2B and 2C demonstrate
that pre-treatment with LY294002 inhibited the phosphorylation
of p38 and JNK (75% and 100% inhibition, respectively).
However, the phosphorylation of ERK1/2 was not affected by
the inhibitor of PI3K (Fig. 2A). These data clearly demonstrate
that, although oxLDL induced the phosphorylation of ERK1/2,
p38 and JNK, only the phosphorylation of p38 and JNK was
mediated by PI3K activation.
Activation of the PI3K/Akt pathway is required for
macrophage responses to oxLDL: upregulation of CD36,
oxLDL uptake and IL-8 production
We then investigated whether PI3K was necessary for the
response of macrophages to oxLDL, namely the upregulation of
CD36 expression, oxLDL uptake and IL-8 production. To this
purpose, human macrophages were pre-treated with LY294002
for 30 min before addition of oxLDL. We found that LY294002
abolished the upregulation of the CD36 expression induced by
oxLDL (Fig. 3A) and significantly inhibited the FITC-oxLDL
uptake (Fig. 3B). Figure 3C shows that the treatment with PI3K
inhibitor also markedly decreased the production of IL-8 by
human macrophages.
CD36 expression induced by oxLDL is dependent on
PAFR and Gai- coupled GPCR
Figure 4A shows that the incubation of human macrophages with
oxLDL increased CD36 protein expression, and this effect was
abrogated by previous treatment with the PAFR antagonist
confirming our previous data [11]. This effect was also observed
at mRNA levels, where two molecularly unrelated PAFR antago-
nists (WEB2170 and CV3988) inhibited the oxLDL-induced CD36
mRNA expression (Fig. 4B). Because the PAFR is a G-coupled
receptor, we sought to investigate the type of Ga-coupled protein
involved in the CD36 expression induced by oxLDL. Thus, human
macrophages were pre-treated with the Gai inhibitor pertussis toxin
(PTX) (600 ng/mL) for 18 h and stimulated with oxLDL (30 mg/
mL) or PAF (1026 M). The expression of CD36 was evaluated after
24 h by FACS. Figures 4A and 4C show that the pre-treatment with
PTX inhibited the expression of CD36 induced by oxLDL (78%
Figure 1. oxLDL activates the PI3k/Akt pathway in a PAFR and Gai coupled protein-dependent manner. Adherent monocytes/
macrophages were treated with WEB2170 (50 mM, 30 min) (A) or PTX (600 ng/mL, 18 h) (B) and stimulated with oxLDL (30 mg/mL) for 10 min.
Western blot analysis of cell lysates were performed using antibodies to phosphorylated and non-phosphorylated forms of Akt. Data are presented as
mean 6 SEM of four donors. Protein expression was quantified by the AlphaEaseFCTM software V3.2 beta (Alpha Innotech). The autoradiographs
show one representative experiment. * p,0.05 comparing oxLDL-stimulated with the non-stimulated cells (cont).# p,0.05 comparing cells treated
with WEB2170 or PTX with non-treated cells.
doi:10.1371/journal.pone.0036632.g001
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inhibition). When the agonist PAF was added to the macrophages, it
increased the expression of CD36 and this effect was also abrogated
by PTX treatment (Fig. 4D). PTX did not affect the cell viability,
measured by MTT assay, which was around 98% in both treated
and non-treated cells (data not shown).
oxLDL induces IL-8 and MCP-1 chemokines in a PAFR-
dependent manner
We found that oxLDL stimulates IL-8 and MCP-1 mRNA
expression in human monocytes/macrophages and this requires
the PAFR activation since the antagonists WEB2170 and CV3988
reduced mRNA levels for those chemokines (Fig. 5A). The
production of IL-8 protein was also dependent on PAFR (Fig. 5B).
Moreover, only oxLDL and not the non-modified LDL was able
to induce IL-8 production in a monocytic cell line, THP-1, in a
dose response-dependent manner.
These results show that PAFR is involved in macrophage
activation by oxLDL to induce chemokine production.
The uptake of oxLDL can occur through PAFR and CD36
separately but co-stimulation of both receptors is
required to induce IL-8 production
HEK293t cells were transiently transfected with plasmids
encoding hPAFR cDNA and hCD36 cDNA (Fig. 6A and 6B).
Figure 2. PI3k/Akt pathway is required for p38 and JNK MAPK activation induced by oxLDL. Adherent monocytes/macrophages were
treated with LY294002 (10 mM, 30 min) and then stimulated with oxLDL (30 mg/mL) for 10 min. The MAPK Western blot analysis of cell lysates were
performed using antibodies to phosphorylated and non-phosphorylated forms of ERK1/2, p38 and JNK (A, B and C, respectively). The
autoradiographs show one representative experiment. Graph data are presented as mean 6 SEM of four donors. Protein expression was quantified
by the AlphaEaseFCTM software V3.2 beta (Alpha Innotech). * p,0.05 comparing oxLDL-stimulated with the non-stimulated cells (cont). # p,0.05
comparing cells treated with LY294002 with non-treated cells.
doi:10.1371/journal.pone.0036632.g002
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The involvement of PAFR and/or CD36 in the oxLDL uptake
was studied by incubation of HEK293t-hPAFR or HEK293t-
hCD36 with FITC-oxLDL, and the uptake was visualized by
fluorescence microscopy. Figure 6C shows that, under the
experimental conditions employed, FITC-oxLDL was taken up
by cells expressing CD36 and, to a lesser extent, by PAFR. In
order to investigate whether both receptors were required for the
IL-8 production induced by oxLDL, HEK293t-transfected cells
were stimulated with oxLDL and after 24 h the IL-8 production
was evaluated in the supernatant (Fig. 6D). It was found that
oxLDL induced IL-8 production only in HEK293t cells co-
transfected with PAFR, in combination with CD36. IL-8 was not
detected in single transfected cells. These data indicated that,
although the uptake of oxLDL can occur separately through each
receptor, the co-stimulation of both receptors is needed to induce
IL-8 production.
Discussion
In a previous study we showed that PAFR is required for
upregulation of CD36 expression and oxLDL uptake by MAPK
pathway activation [11]. Here we showed that the addition of
oxLDL to human monocytes/macrophages activates the PI3K/
Akt pathway which in turn activates the p38 and JNK MAPK.
Phosphorylation of Akt requires the engagement of PAFR and a
Gai-coupled protein. This leads to increased expression of CD36,
IL-8 and MCP-1 mRNA and is also PAFR-dependent (Fig. 7). By
transfecting CD36 and PAFR to HEK 293t cells, we found that
whereas each receptor per se was able to induce oxLDL uptake
both receptors were required for IL-8 production.
It has been reported that oxLDL activates several receptors
expressed in macrophages and contributes to the inflammatory
response present in early and advanced atherosclerotic lesions
Figure 3. PI3K/Akt pathway is required for oxLDL induced upregulation of CD36 expression (A) oxLDL uptake (B) and IL-8
production (C). Adherent human monocytes/macrophages were treated with LY294002 (10 mM, 30 min), and then stimulated with oxLDL (30 mg/
mL) for 24 h. The expression of CD36 was measured by FACS and IL-8 production by ELISA. For the uptake evaluation, stimulated cells were washed
and incubated with FITC-oxLDL for 1 h and uptake was measured by FACS. Data are presented as mean6 SEM of the mean fluorescence Intensity of
five donors. * p,0.05 comparing oxLDL stimulated with non-stimulated cells (cont). # p,0.05 comparing cells treated with LY294002 with non-
treated cells.
doi:10.1371/journal.pone.0036632.g003
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[13]. This is possibly because oxLDL is not a single particle but
a number of oxidized compounds that might interact with
different receptors and promote various intracellular activation
pathways [10,14]. These multiple effects explain why the detailed
mechanism involved in macrophage activation induced by
oxLDL, and the intracellular pathway to foam cell formation are
not fully understood. Therefore, it is important to characterize
the signals induced by oxLDL in the cells that participate in the
atherosclerotic lesion, and to determine which signals are relevant
in the pathogenesis of atherosclerosis. It has been shown that
MAPK activation is required for foam cell formation and
atherosclerotic lesion in animal models [15,16]. Our results
using human cells show that the phosphorylation of p38 and
JNK induced by oxLDL, which is required for the uptake of
oxLDL, is dependent on PI3K/Akt activation. Moreover, a PAFR
antagonist and a Gai inhibitor decreased the phosphorylation
of Akt, which is known to be a downstream target protein for
PI3K and a critical player in promoting the macrophage survival
by virtue of its anti-apoptotic mechanisms [17]. These results
suggest that the activation of PAFR and Gai-coupled receptor,
induced by the interaction of oxLDL with macrophages, induces
the PI3K/Akt activation pathway and MAPK phosphorylation
which are necessary for the upregulation of CD36 expression,
oxLDL uptake and IL-8 production. One possible mechanism
responsible for CD36 expression involves the activation of
PPARc [2] and Nrf2 [18] which have been described as the
main pathways and might be a downstream pathway for PI3K/
Akt activation [17]. However, the importance of the PI3k-
Akt-PPARc-CD36 or PI3k-Akt-Nrf2-CD36 pathways has never
been addressed.
We previously reported that ERK1/2 inhibition reduced the
expression of CD36 [11]. In this work the PI3K inhibitor reduced
the expression of CD36 without affecting the ERK1/2 phosphor-
ylation. Together these results are very interesting and we can
speculate that the downstream molecules from ERK1/2 and Akt
pathways might interact synergistically to induce CD36 expres-
sion. Corroborating this hypothesis, it was demonstrated that
ERK1/2 and Akt inhibitors impair cell proliferation and tumor
growth synergistically even though Akt was not involved in
ERK1/2 phosphorylation [19].
Several pro-inflammatory cytokines and chemokines related to
atherosclerosis progression have been observed in macrophages
stimulated by oxLDL and compounds present in the oxLDL
particle [20]. We found that macrophages stimulated with oxLDL
produced high IL-8, an effect inhibited by the PAFR antagonist
and PI3K inhibitor. The production of IL-8 is dependent on
MAPK phosphorylation, which activates the nuclear factor AP-1
and stabilizes IL-8 mRNA [21]. This chemokine was first
described as a mainly neutrophil chemoattractant, and probably
because of this there is a lack of information regarding the role of
IL-8 in atherogenesis. It is now known, however, that IL-8 plays an
early and important role in recruitment of monocytes to
atherosclerotic lesions [22]. Moreover, chronic IL-8 production
also triggers hyperplasia, leading to vessel wall thickening and
acceleration of the atherogenic process [7]. Our data suggest that
the PAFR is required not only for oxLDL uptake but also for IL-8
and MCP-1 production, which are important for the recruitment
of monocytes to the subendothelial space. More importantly, IL-8
has recently been indicated as a potential marker of atherosclerotic
disease [23].
Figure 4. PAFR and Gai-coupled protein is required for upregulation of CD36 protein and mRNA expression. Adherent human
monocytes/macrophages were treated with WEB2170 (50 mM, 30 min) or with pertussis toxin (PTX - 600 ng/mL, 18 h) and then stimulated with
oxLDL (30 mg/mL) or PAF (1026 M). The expression of CD36 was measured by FACS after 24 h (A, C and D) and the mRNA levels after 5 h (B). Data are
presented as mean 6 SEM of the mean fluorescence intensity of five donors (A–B) or one representative experiment (C–D). * p,0.05 comparing
oxLDL stimulated with non-stimulated cells (cont). # p,0.05 comparing cells treated with PTX, WEB2170 or CV3988, with non-treated cells.
doi:10.1371/journal.pone.0036632.g004
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Regarding the involvement of PAFR in atherosclerosis, it is
known that foam cells produce high amounts of PAF [24,25]. Only
one study has shown that treatment with PAFR antagonists
reduced the formation of fatty streaks lesions, which are the first
stage in atherosclerosis development [26]. However, the role of
PAFR in mechanisms related to advanced atherosclerotic plaque
has never been addressed. The scavenger receptor CD36 has a
very short intracytoplasmatic tail and there are still conflicting data
regarding the mechanisms of signal transduction mediated by this
receptor. CD36 does not appear to signal on its own in response to
stimuli but it has been shown that, depending on the structural
characteristics of the ligand, it might collaborate with TLR2,
TLR4 and TLR6, resulting in different cell responses [13,27].
oxLDL is a complex particle, formed by several oxidized
phospholipids that interact with CD36 and PAFR and little is
known about the influence of this interaction on cell activation. To
address these questions, we used human cell-based models in
which CD36 and/or PAFR were over-expressed in HEK293t cell
lines. This cell line was selected because of non-existent levels of
receptors, allowing dissection of direct CD36- and PAFR-
mediated signaling. The obtained results showed that both
receptors, PAFR and CD36, are able to bind the oxLDL but
only the co-stimulation of CD36 and PAFR by oxLDL was able to
induce the production of IL-8. These data suggest that although
PAFR and CD36 can independently promote the uptake of
oxLDL, only the co-stimulation of both receptors is able to
transduce intracellular signaling for IL-8 production, thus
indicating a crosstalk between receptors for PAF and oxLDL.
Our study did not show at what level the interaction between
CD36 and PAFR occurs. If these receptors are stimulated in
parallel, or if oxLDL can recruit both classes of receptors to
specific membrane microdomains called lipid rafts, then this would
allow these receptors to be in close proximity and induce a
favorable environment for their association. In our study, we
focused on PAFR and CD36 but several innate immune receptors
have been shown to mediate cell activation by oxLDL [13,27]. It is
therefore possible that other receptors might have a role in this
assembly and in increasing cell activation.
In conclusion, the intracellular signaling pathways activated by
oxLDL are dependent on PAFR and play a pivotal role in
mediating the oxLDL uptake and consequently have functions in
foam cell formation. Additionally, this study shows that oxLDL
interacts with CD36 and PAFR to induce IL-8 and MCP-1, which
are involved in the recruitment of monocytes and may contribute
to inflammatory processes. Thus, PAFR could become a
promising target for atherosclerosis treatment.
Figure 5. oxLDL induces IL-8 and MCP-1 in a PAFR-dependent manner. Adherent human monocytes/macrophages were treated with
WEB2170 (50 mM) or CV3988 (10 mM) for 30 min and stimulated with oxLDL (30 mg/mL). The mRNA levels for MCP-1 and IL-8 were evaluated after 5 h
(n = 4) (A). The IL-8 concentration was measured in the supernatants after 24 h (n = 3) (B). THP-1 cells stimulated with different concentrations of
oxLDL or LDL, the IL-8 concentration was measured after 24 h (C). Data are presented as mean 6 SEM. * p,0.05 comparing oxLDL stimulated with
non-stimulated cells (cont). # p,0.05 comparing cells treated with WEB2170 or CV3988 with non-treated cells.
doi:10.1371/journal.pone.0036632.g005
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Materials and Methods
Materials
Fetal calf serum (FCS), RPMI-1640, L-glutamine and HEPES
acid were purchased from Gibco (Long Island, NY, USA);
penicillin, streptomycin, aprotinin, leupeptin, benzamidin, chlor-
amphenicol, protease inhibitor cocktail, PMSF, pertussis toxin
from Bordetella pertussis, MTT (methylthiazolyldiphenyl-tetrazo-
lium bromide) and the Ficoll Hypaque gradient: HistopaqueH-
1077 from Sigma-Aldrich (St. Louis, MO, USA); the PI3K
inhibitor LY294002 and the PAFR human polyclonal antibody
from Cayman Chemical (Ann Arbor, Michigan, USA); the
monoclonal phycoerythrin (PE)-anti-hCD36 and isotype control
PE-mouse IgM from BD Biosciences (Franklin Lakes, NJ, USA);
the monoclonal antibodies to phosphorylated and non-phosphor-
ylated forms of ERK1/2, p38, JNK, Akt and anti-rabbit IgG-HPR
from Cell Signaling Technology (Beverly, MA, USA); the Qiagen
plasmid midi Kit from Qiagen Inc. (Valencia, CA, USA); the
LipofectamineTM 2000 from Invitrogen by Life Technologies
(Carlsbad, CA, USA); the ECL reagent kit and the nitrocellulose
membrane for western blot from GE Healthcare (Uppsala,
Sweden); the Ficoll–Hypaque from Amersham-Pharmacia Biotech
(Uppsala, Sweden); the BCA kit from Thermo Scientific (Rock-
ford, IL, USA); PAFR antagonists: CV3988 was purchased from
Biomol (Enzo Life Sciences, New York, USA) and WEB2170 was
kindly supplied by Boehringer Ingelheim (Pharma KG, Biberach,
Germany).
Purification and oxidation of LDL
The study was approved by the ethics committee of the Institute
of Biomedical Sciences, University of Sao Paulo. Blood was
collected from normolipidemic volunteers and plasma was
obtained after centrifugation at 1,000 g, 4uC, for 15 min in the
presence of EDTA 1 mg/mL. Thereafter, we added benzamidine
(2 mM), gentamicin (0.5%), chloramphenicol (0.25%), PMSF
(phenyl-methyl-sulfonyl-fluoride) (0.5 mM), and aprotinin (0.1
Figure 6. CD36 and PAFR cooperatively mediate FITC-oxLDL uptake and IL-8 production. HEK 293t cells were transiently transfected with
hCD36 and/or hPAFR, as described in methods (A–B). Transfected cells were incubated with FITC-oxLDL (30 mg/mL) for 1 h at 37uC. Cells were washed
and fixed with paraformaldehyde 4%. Fluorescence was visualized by microscopy (C). Transfected cells were stimulated with oxLDL (30 mg/mL) and
the IL-8 concentration in the supernatant was measured after 24 h (D). * p,0.05 comparing with cDNA3 plasmid control transfected cells.
doi:10.1371/journal.pone.0036632.g006
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units/mL). LDL (1.019–1.063 g/mL) was isolated by sequential
ultracentrifugation (100,000 g, 4uC), using a P90AT-0132 rotor
(CP70MX ultracentrifuge; Hitachi Koki Co., Ltd, Tokyo, Japan),
dialyzed (4uC) against PBS, pH 7.4 containing 1 mM EDTA,
filtered (0.22 mm) and stored at 4uC. The protein concentration
was determined by the BCA kit. Part of the LDL was dialyzed
overnight against EDTA-free PBS, followed by incubation with
CuSO4 (20 mM per mg of LDL protein/18 h/37uC). The
oxidation was stopped by the addition of EDTA 1 mM. This
procedure has been previously standardized and results in
completely oxidized LDL [28].
Cell culture
Peripheral blood mononuclear cells (PBMC) were separated by
a Ficoll–Hypaque gradient (density 1.077 g/mL) according to the
manufacturer’s instructions, resuspended and cultured in RPMI-
1640 supplemented with 5% FCS, 15 mM HEPES, 2 mM L-
glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin.
Cell cultures were maintained in a humidified atmosphere
containing 5% CO2 at 37uC. After 1 h, the non-adherent cells
were washed out with warm PBS and the adherent monocytic cells
were cultured in RPMI/10% FCS for 72 h. The monocytic cell
line THP-1 cells were cultured in RPMI/10% FCS. One day
before the experiments, the medium was changed for RPMI/2%
FCS.
Flow cytometry for CD36 expression
Macrophages were cultured in the presence of oxLDL for 24 h.
The PAFR antagonists WEB2170 or the inhibitors of PI3 kinase
(LY294002) were added to the cell cultures 30 min before the
addition of oxLDL. After the incubation time, the cell culture
medium was replaced with cold PBS and plates were put on ice for
30 min, after that, the cells were scraped with a rubber policeman
cell, centrifuged at 3006g for 10 min, washed and resuspended in
staining buffer (PBS, FCS 1%, sodium azide 0.1%) containing the
labeled monoclonal antibodies, PE-conjugated anti-human CD36
or the isotype control, diluted 1:100. The expression of CD36 was
evaluated in a flow cytometer (FACS Canto II - Becton BD
Biosciences) and the data were analyzed by the software SummitH
V4.3 (DakoCytomation). During the acquisition, the doublets were
excluded using gates in FSC-A vs FSC-H. The autofluorescence of
macrophages was removed at the beginning of the analyses.
Uptake of oxLDL
LDL was labeled with FITC, as described previously [29,30].
The FITC concentration in LDL was determined by spectroscopy
against FITC standard solution at 495 nm. The F/P (fluoro-
chrome/protein) molar ration was calculated as described and
admitted in the range of 2.4 to 3 [31]. FITC-LDL was oxidized by
CuSO4 (20 mM per mg of LDL protein; 18 h; 37uC). To
investigate the role of the PI3K in the uptake of oxLDL,
monocytes/macrophages were treated with LY294002 (10 mM)
for 30 min, then incubated with oxLDL (30 mg/mL). After 24 h,
the cells were washed twice with RPMI/5% FCS to remove the
oxLDL from the supernatant and incubated overnight in RPMI/
5% FCS. This procedure was performed to allow the upregulation
of CD36 in the plasma membrane. The uptake assay was
performed by incubation with FITC-oxLDL for 1 h at 37uC.
Cells were washed with cold PBS and fixed with 2% formalde-
hyde. The uptake of FITC-oxLDL was evaluated by flow
Figure 7. Based on these results we conclude that the addition of oxLDL to human monocytes/macrophages activates the PI3K/Akt
pathway which in turn activates the p38 and JNK MAPK. Phosphorylation of Akt requires engagement of PAFR and a Gai-coupled protein.
This should lead to NFkB and/or AP-1 activation and gene transcription. We found increased expression of CD36, IL-8 and MCP-1 mRNA in cells
stimulated with oxLDL in a PAFR-dependent manner. Moreover, we observed increased expression of CD36 protein on macrophage membrane and
increased uptake of oxLDL by these cells upon exposure to oxLDL which were also dependent on PAFR. By transfecting CD36 and PAFR to HEK 293t
cells, we found that whereas each receptor per se was able to induce oxLDL uptake, both receptors were required for IL-8 production. These results
point to an important role for PAFR in atherosclerosis by promoting foam cells formation because of the increased uptake of oxLDL and also by
contributing to macrophage infiltration due to IL-8 and MCP-1 production. Thus, antagonists of PAFR might be a promising target for atherosclerosis
treatment. Dashed lines represent data obtained from the literature [21].
doi:10.1371/journal.pone.0036632.g007
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cytometry using a FACS Canto II (Becton BD Biosciences) and
analyzed using software SummitH V4.3 (DakoCytomation).
Western blot for ERK1/2, p38-MAPK, JNK and Akt
Human monocytes/macrophages (26106 cells/ml) were pre-
treated with LY294002 (10 mM) for 30 min, then treated with
oxLDL for 10 min. Cells were washed with cold PBS and protein
lysates were obtained by homogenizing cells in lysis buffer (1%
NonidetH P40, 50 mM Tris, pH 8.0, 150 mM NaCl, SDS 0.1%)
supplemented with a protease inhibitor cocktail and phosphatase
inhibitors (10 mM sodium fluorate and 1 mM sodium orthova-
nadate). Protein concentrations were determined using with the
BCA assay kit. Equal amounts of protein (15 mg) were separated
by SDS-PAGE (10%) and transferred to a nitrocellulose mem-
brane. The phosphorylated and total non-phosphorylated proteins
were detected using monoclonal antibodies to ERK1/2, p38, JNK
and Akt. Proteins were visualized using with horseradish
peroxidase-conjugated IgG anti-rabbit (1:1,000 dilution, 1 h) and
the ECL system. The resulting autoradiograms were analyzed with
the AlphaEaseFCTM software V3.2 beta (Alpha Innotech).
mRNA expression
RNA was isolated using TRIzol reagents (Life-Technologies).
For the real-time reverse-transcriptase polymerase chain reaction
(PCR), cDNA was synthesized using the RevertAidTM First
Strand cDNA Synthesis Kit (Fermentas Life Sciences, Ontario,
USA), according to the manufacturer’s instructions. PCR-master
mix (Power SyBrH Green, Applied Biosystems, Warrington, UK)
containing the specific primers was then added. hCD36 forward:
TCAGCAAATGCAAAGAAGGGAGAC and reverse: GGTT
GACCTGCAGCCGTTTTG, IL-8 forward: ACTGAGAGTGA
TTGAGAGTGGAC and reverse: AACCCTCTGCACCCAG
TTTTC, hMCP-1 forward: CAGCCAGATGCAATCAATGCC
and reverse: TGGAATCCTGAACCCACTTCT and GAPDH
forward: GAGTCAACGGATTTGGTCGT and reverse: TTGA
TTTTGGAGGGATCTCG. Real-time PCR was performed
using a Stratagene Mx3005PTM QPCR Systems (Santa Clara,
CA, USA). Relative gene expression was calculated by the 22Delta
Delta C(T) method as previously described [32]. Data are shown in
fold increase related to untreated cells.
MTT assay
The mitochondrial-dependent reduction of methylthiazolyldi-
phenyl-tetrazolium bromide (MTT) to formazan insoluble crystals
was used to evaluate cell viability. Briefly, 500 mg/ml of MTT in
RPMI were added to the cells after the treatments. Cells were
incubated for 3 h at 37uC in a 5% CO2 atmosphere. After that a
SDS 10% in HCl 0.01 M solution was added to the cells to
dissolve the crystals and the absorbance was measured after 14 h
in a Dynatech microplate reader at 570 nm.
Transfection of HEK 293t cells
HEK 293t cells were cultured in RPMI-1640 supplemented
with 10% FCS, 15 mM HEPES, 2 mM L-glutamine, 100 U/mL
penicillin and 100 mg/mL streptomycin. The plasmids hCD36-
pcDNA3.2/V5-DEST, pcDNA3-kozac-myc-hPAFR and the con-
trol plasmid pcDNA3 were purified using the Qiagen Plasmid Kit.
The day before the transfection, HEK 293t cells were seeded onto
24-well plates at a density of 26105 cells/well. The cells were
transiently transfected with 2 mg of total plasmid DNA per well
Lipofectamine-2000 according to the manufacturer’s instructions.
At 48 h after transfection, the cells were used for the experiments.
The efficiency of the transfection was assessed by flow cytometry
using PE-conjugated anti-human CD36 and by western blot using
rabbit anti-hPAFR antibody.
Measurement of IL-8 secretion
The IL-8 present in the supernatant of PMBC and HEK 293
transfected cells was evaluated by ELISA (BD Biosciences).
Statistical analysis
Data are presented as mean 6 SEM. Analysis of variance
(ANOVA) and Student-Newman-Keuls post-test were used to
evaluate the statistical significance of the differences. Significance
was assumed if p,0.05.
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